This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Winners & Losers: Inspire

Health stocks traded heavily into negative territory along with the broader markets on a relatively quiet Friday for the sector.

The Nasdaq and Amex biotechnology indices took gave up 1.8% and 1.8%, respectively, after registering gains a day earlier.

One component of the Nasdaq index that bucked the trend, Inspire Pharmaceuticals (ISPH) surged $1.39, or 36%, to $5.24 after the company said a late-stage trial of inhalation solution Denufosol, its prospective cystic fibrosis drug, met its primary goal.

In business news, GlaxoSmithKline (GSK) said Friday that it completed its previously announced purchase of Sirtris Pharmaceuticals through a cash and tender offer of roughly $720 million, or $22.50 a share. Glaxo's shares were off by 75 cents, or 1.7%, at $42.50.

Also GenVec (GNVC) said it will sell some 11.25 million shares of common stock and warrants to purchase about 2.25 million more to institutional and accredited investors for proceeds of roughly $17 million. Shares were down 19 cents, or 11%, at $1.49 on higher-than-average volume.

Meanwhile, Natus Medical (BABY) shares turned down a day after the company raised revenue guidance but reined in its full-year profit expectations in light of its acquisition of privately held Sonamed Corp. and two stock offerings earlier this year. Shares, which rose 33 cents Thursday, gave up 77 cents, or 3.6%, to $20.35 Friday.

Elsewhere, the Food and Drug Administration outlined proposals regarding the safety of contact lens solutions ahead of an advisory panel scheduled for next Tuesday, according to an Associated Press report.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,568.11 +211.24 1.22%
S&P 500 2,034.67 +21.78 1.08%
NASDAQ 4,700.8980 +56.5860 1.22%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs